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Abstract 
Through the last decade, cold atmospheric plasma (CAP) has emerged as an innovative therapeutic option for cancer 
treatment. Recently, we have set up a potentially safe atmospheric pressure plasma jet device that displays antitumoral 
properties in a preclinical model of cholangiocarcinoma (CCA), a rare and very aggressive cancer emerging from the biliary 
tree with few efficient treatments. In the present study, we aimed at deciphering the molecular mechanisms underlying 
the antitumor effects of CAP towards CCA both in an in vivo and in vitro context. In vivo, using subcutaneous xenografts 
into immunocompromised mice, CAP treatment of CCA induced DNA lesions and tumor cell apoptosis, as evaluated by 
8-oxoguanine and cleaved caspase-3 immunohistochemistry, respectively. Analysis of the tumor microenvironment 
showed changes in markers related to macrophage polarization. In vitro, incubation of CCA cells with CAP-treated culture 
media (i.e. plasma-activated media, PAM) led to a dose response decrease in cell survival. At molecular level, CAP 
treatment induced double-strand DNA breaks, followed by an increased phosphorylation and activation of the cell cycle 
master regulators CHK1 and p53, leading to cell cycle arrest and cell death by apoptosis. In conclusion, CAP is a novel 
therapeutic option to consider for CCA in the future. 
Keywords Cholangiocarcinoma; cold plasma; innovative therapy; tumor cells; macrophages; plasma selectivity; plasma jet 
I. Introduction 
 
Cholangiocarcinoma (CCA) is a tumor of the biliary tree with 
poor prognosis characterized by a dense desmoplastic stroma [1]. 
CCA is a rare tumor. Currently CCA accounts for 3% of all 
gastrointestinal cancers but overall, its incidence tends to increase 
worldwide. So far, surgical resection of the tumor is the only 
curative and effective therapeutic option. However, this cancer is 
usually diagnosed at advanced stage so that this treatment is 
feasible in a small proportion of patients and recurrence is high. 
When tumor resection is not possible or when recurrence occurs, 
the therapeutic alternatives consist in palliative treatments based 
on chemotherapy regimens with poor results [2]. Hence, there is a 
need of new therapeutic approaches.  
Cold atmospheric plasma (CAP) (named also non-thermal 
plasma or low temperature plasma) is a weakly ionized gas created 
by electrical discharges, composed of transient, energetic and 
chemical active species (electrons, ions, metastables, radicals) that 
displays radiation, gas dynamics and electric field properties. 
Today, CAP interaction with biological systems (cells, tissues, 
tumors) is studied to address medical issues such as blood clotting, 
wound healing, dentistry, repair surgery, cosmetics, infectious and 
inflammatory diseases, and oncology [3]. CAP science and 
technology appear as a new research avenue to provide 
breakthrough solutions where conventional therapies in cancer 
appear limited [3]. Indeed, plasmas can reduce cell proliferation or 
tumor volume in preclinical mice models, in several types of 
cancers including skin, pancreatic, bladder, colon [4,5]. Therefore, 
plasmas have major potential in driving antitumor effects, notably 
in resistant tumors such as CCA. The primary action of CAP is to 
generate long-lived molecules such as reactive oxygen and 
nitrogen species (RONS) mainly from nitrogen and oxygen in 
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atmospheric air or solution. This action can be either beneficial or 
deleterious on living tissues depending on their concentrations. 
RONS are primarily responsible for anti-tumor activity of CAP. They 
drive cell cycle arrest and cell death by damaging DNA and 
regulating cancer-relevant molecules such as the tumor 
suppressor p53 [6,7].  
To date, only two studies addressed the potential of CAP to treat 
liver tumors [5,8]. In these studies, CAP was tested on 
hepatocellular carcinoma cell lines and induced cell death. To 
investigate CAP as a potential new therapeutic option, we 
previously engineered a new cold plasma jet device that showed 
significant antitumor effects in a mouse CCA model, without 
inducing toxic effects on heathy tissue [9]. Here, we aim to gain 
insight into the molecular mechanisms by which CAP halts CCA 
development and progression in vivo and in vitro. In addition, we 
investigated whether CAP has an effect on non-tumoral cells 
notably hepatocytes, the parenchymal liver cells. Evidence was 
previously provided to indicate that CAP induced cell death 
selectively in tumor cells and not in non-malignant cells [3]. The 
tumor itself is a complex tissue structure including cells of the 
tumor microenvironment such as cancer-associated fibroblasts 
(CAF), endothelial cells (EC) and tumor-associated macrophages 
(TAM). Therefore, we also evaluated in vivo the impact of CAP on 
these cell populations. 
II. Results 
 
II.1. CAP treatment reduces cholangiocarcino-
ma progression in a murine xenograft model 
 
We previously compared two CAP generating devices, i.e. Plasma 
Gun (PG) and Plasma Tesla Jet (PTJ), showing that both devices 
were safe but differed with respect to anticancer properties [9]. 
Only PTJ (Figure 1a) displayed a significant therapeutic efficacy in 
a subcutaneous xenograft model of CCA [9]. In the present study, 
we used the same model to further analyze the molecular 
mechanisms accounting for PTJ effects in the same preclinical 
model. To better assess the effect of CAP on CCA growth, we 
compared its effect with that of gemcitabine, one of the 
chemotherapeutic drugs currently used in CCA patient treatment. 
EGI-1 CCA cells were injected to induce tumors in the flank of 
immunodeficient mice and once the tumors reached an arbitrary 
volume of 200 mm3, we applied CAP directly on the tumors (Figure 
1b) or we administrated gemcitabine by intraperitoneal injection 
twice a week for 3 weeks (see red arrows in Figure 1c). Animals 
were sacrificed 2 hours after the last treatment. As shown in Figure 
3 c-e, tumor size and growth rate were significantly reduced after 
the application of CAP consistently with our previous results [9]. 
The well-established antitumoral effect of gemcitabine was 
evident and exceed that of CAP [10]. To verify that local CAP 
treatment did not induce side effects in the whole organism, we 
measured the plasma concentrations of alanine aminotransferase 
(ALAT) and aspartate aminotransferase (ASAT) as well as lactate 
dehydrogenase (LDH) in treated mice. No significant difference of 
concentration was observed between CAP treated animals and 
controls. By contrast, ASAT and LDH were significantly increased in 
the animals that received gemcitabine, indicating liver damage. 
These results show the advantage of direct CAP treatment which 
remains local over the systemic effects of gemcitabine but also less 
toxic. If, at first sight, CAP may appear less efficient than 
gemcitabine, one has to underline that CAP exposure times were 
as low as 1 min while the lifetime of gemcitabine injected in the 
organism is several hours. 
 
 
Figure 1. (a) Experimental setup of the Plasma Tesla Jet device (PTJ). (b) 
Schematic representation and representative image of the cold 
atmospheric plasma (CAP) application to subcutaneous xenograft CCA 
tumors. (c) Tumor volume of mice bearing CCA developed from EGI-1 cells 
treated with gemcitabine (120 mg/kg, black circles), CAP (1 min at 9kV of 
amplitude, frequency=30kHz, duty cycle=14%, gap=10 mm, purple circles) 
or untreated (control, white circles). Arrows indicate treatments points 
with CAP and gemcitabine. (d) Tumor weight at sacrifice (day 35). (e) 
Representative images of tumors from each group at sacrifice. (f) 
Plasmatic concentrations of alanine aminotransferase (ALAT), aspartate 
aminotransferase (ASAT) and lactate dehydrogenase (LDH). Values are 
expressed as means ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, 
p < 0.0001. 
 
 
This document is a pre-print version. You may use it at your own convenience although its content may deviate in places from the final published article. 
 
3 
J. Vaquero, F. Judée, M. Vallette, H. Decauchy, A. Arbelaiz, L. Aoudjehane, O. Scatton, E. Gonzalez-Sanchez, F. Merabtene, J. Augustin, C. Housset, T. 
Dufour, L Fouassier, Cancers, 12, 1280 (2020), https://doi.org/10.3390/cancers12051280 
 
II.2. Cold atmospheric plasma induces 
apoptosis in cholangiocarcinoma cells in vivo 
 
To further evaluate the effect of CAP on CCA xenografts, we 
performed a histological analysis of the tumors. A deep analysis 
revealed the presence of purple round structures that represent 
calcifications (Figure 2a and b). These calcifications are often 
associated with apoptotic bodies and may represent a late state of 
condensed apoptotic structures. The quantification showed an 
increased number of calcifications in tumors treated with CAP or 
gemcitabine compared to controls (Figure 2c). 
 
 
 
Figure 2. (a) Representative HE staining of control (upper panel), CAP 
(middle panel) and gemcitabine (bottom panel) treated xenograft 
tumors. Magnification x125. Scale: 500 μm. (b) Magnification (x1000) of 
calcifications corresponding to apoptotic bodies (outlined in yellow). 
Scale: 50 μm. (c) Quantification of apoptotic structures. ***, p < 0.001; 
compared with control tumors. 
 
The presence of these calcifications prompted us to study 
apoptosis, the main type of cell death related to CAP, by 
performing immunostaining against cleaved caspase-3 (cCaspase-
3), a critical executioner of apoptosis that is responsible for the 
cleavage of many key proteins. As shown in Figure 3 (left panels), 
animals treated with CAP showed an intense staining of cCaspase-
3 in some areas of the tumors compared to the controls. This 
staining was also present but weaker in animals that received 
gemcitabine and even stronger in the CAP group. These 
differences that can be explained by the time at which the animals 
were sacrificed, i.e. approximately 2 hours after their CAP or 
gemcitabine treatments. Since CAP is applied locally, its effects 
operate faster than drugs delivered intraperitoneally such as 
gemcitabine. Indeed, this drug must be first absorbed and then 
transported to the tumors. In that latter case, the therapeutic 
effects of gemcitabine may be observed later than 2 hours. 
Since one of the main effects of CAP is the production of RONS, we 
evaluated the presence of cellular components altered as a result 
of reactive species overload, more specifically 8-oxoguanine, one 
of the major products of DNA oxidation, as an event that could 
unchain the signaling pathways leading to cell death by apoptosis. 
As shown in Figure 3 (right panels), CAP treatment was able to 
strongly induce DNA alterations. In addition, it is worth noting that 
these alterations were colocalized with the areas positive for 
cleaved caspase-3 (left panels). This perfect overlapping enables 
us to bridge DNA damage with cell apoptosis. Interestingly, there 
was no staining of 8-oxoguanine in tumors from the group that 
received gemcitabine, showing that the main effects of this drug 
are not mediated by reactive species related molecular 
mechanisms. 
 
 
Figure 3. Representative IHC staining of cleaved caspase-3 and 8-
oxoguanine in control (upper panel), CAP (middle panel) and gemcitabine 
(bottom panel) treated xenograft tumors. Magnification, x250. Scale: 200 
μm. 
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II.3. Cold atmospheric plasma reduces 
viability of cholangiocarcinoma cells but not 
of normal hepatocytes in vitro 
 
Next, we performed in vitro studies on CCA cell lines to further 
dissect the effects induced by CAP on tumor cells. First, we 
evaluated the effects of CAP treatment on the viability of two 
human CCA cell lines, EGI-1, the same cell line used for the 
induction of subcutaneous xenografts, and HuCCT1. Besides, to 
verify if CAP treatment is biologically selective, non-malignant 
primary human hepatocytes, the main cell type in the liver, where 
isolated from patients. They were also exposed to the same CAP 
treatment to verify if CAP may drive to side effects. To standardize 
the application of CAP across the different in vitro experiments, 
first we treated by plasma a standard volume of fresh culture 
media (3 mL) in a standardized plastic support (6-well plates) for 3 
min. Second, we incubated the resulting plasma-activated culture 
media (commonly called PAM) with either CCA cell lines or human 
hepatocytes in culture (Supplementary Figure 1). Such indirect 
CAP treatment induced a decrease in the viability of CCA cells and 
this effect became stronger for CAP exposure times increasing 
from 1 to 10 minutes (Figure 4a). In contrast, no effect was 
observed on the viability of human hepatocytes isolated from 3 
different patients (Figure 4a), hence demonstrating a selective 
effect of CAP on tumor cells over non-malignant liver cells. Of note, 
similar experiments performed after exposure to gemcitabine 
showed a dose-dependent decrease in cell viability that was more 
pronounced in CCA cells but reached approximately a 30% 
reduction in hepatocytes (Figure 4b), demonstrating a better 
selectivity of CAP over gemcitabine. Since CCA cell lines and 
primary hepatocytes need different culture media due to specific 
requirements of each cell type, we evaluated the production of 
RONS in media. More specifically, we determined the 
concentration of NO2 and H2O2 in CAP-exposed culture media at 
different time points, the same used in cell viability studies. While 
the production of NO2 remains overall the same over treatment 
time  in both types of media (Figure 4c), production of H2O2, was 
approximately 6 times higher in hepatocyte media than in CCA 
media (Figure 4d). To get more insight on this issue we determined 
the generation of ROS in cell lysates from CCA cells and 
hepatocytes exposed to PAM. Interestingly, production of H2O2 
was only increased in CCA cells exposed to PAM, while it remained 
unchanged in hepatocytes (Figure 4e). This observation led us to 
think about potential defense mechanisms protecting hepatocytes 
from ROS production, more specifically, ROS-scavenging enzymes. 
Indeed, further analysis revealed that mRNA expression of several 
enzymes was strongly increased in hepatocytes compared to both 
CCA cell lines (Figure 4f). Altogether, these results validate the 
selective effect of CAP-activated medium in CCA cells over 
hepatocytes. 
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Figure 4. (a-b) Effect of CAP (a) and gemcitabine (b) on the viability of EGI-
1 and HuCCT1 CCA cells and human primary hepatocytes. Cell viability 
was measured after incubation for 72 hours with culture medium 
previously treated for 1, 3, 5 and 10 min with CAP (9kV, 30kHz, 14%, gap 
of 7 mm). (c-d) NO2 (c) and H2O2 (d) determination in culture media from 
CCA cells and primary hepatocytes. (e) H2O2 determination in cell lysates 
from CCA cells and primary hepatocytes exposed to PAM for 3 min. (f) 
Expression of GSTA4, MSRB3, SOD1, SOD2, CAT2 and HMOX1 at mRNA 
level in CCA cell and hepatocytes. Values are expressed as means ± SEM 
from at least 3 independent cultures. *, p < 0.05; **, p < 0.01; ***, p < 
0.001; compared with untreated cells (0 min). 
 
II.4. Cold atmospheric plasma induces cell 
cycle arrest and apoptosis in cholangio-
carcinoma cells  
 
As previously underlined, CAP-derived RONS drive cell cycle arrest 
and cell death by damaging DNA [6,7]. For the following 
experiments we used the IC50 from the viability assays (Figure 4a), 
corresponding to 3-min treatment with CAP. Therefore, we 
evaluated the possibility of cell cycle arrest in our experimental 
conditions. Indeed, flow cytometry analysis of cell cycle 
distribution showed changes in the different phases (Figure 5). 
Both EGI-1 and HuCCT1 cells experienced a decrease in the 
percentage of cells in G0/G1 phases and S, and an increase of the 
percentage of cells in G2/M phases. 
 
 
Figure 5. (a-d) Representative flow cytometry cell cycle measurement (a, 
c) and graphical representation of the cell cycle distribution (b, d) of EGI-
1 (a-b) and HuCCT1 (c-d) CCA cells after 24h of exposure to culture 
medium pretreated with CAP for 3 min (9kV, 30kHz, 14%, gap of 7 mm). 
Cell populations in G0/G1, S, and G2/M phases are given as percentage 
of total cells. Values are expressed as means ± SEM from at least 3 
independent cultures. *, p < 0.05; compared with control cells. 
 
The accumulation of cells in G2/M indicate that cells arrested 
the cell cycle at the G2/M DNA damage checkpoint, that serves to 
prevent cells with genomic DNA damage from entering the M 
phase. Therefore, our next step was to determine if, as observed 
in vivo, CAP treatment could drive DNA damage in CCA cells in 
vitro. One of the most important proteins required for checkpoint-
mediated cell cycle arrest and DNA repair following double-
stranded DNA breaks is the histone H2AX. DNA damage caused by 
oxidative stress results in a rapid phosphorylation of H2AX (named 
H2AX), leading to the recruitment of several proteins in response 
to DNA damage. Immunofluorescence analysis showed a strong 
staining of phospho-histone H2AX in both EGI-1 and HuCCT1 cells 
at different times (i.e. 24h, 48h and 72h) after exposure to CAP-
activated culture medium compared to untreated cells (Figure 6a 
and d), being 72h in EGI-1 and 48h in HuCCT1 cells, the highest 
signal, as ascertained by western blot (Figure 6b-c and e-f). 
Western blot analyses showed a clear correlation between the 
increase of histone H2AX phosphorylation and PARP cleavage 
(Figure 6b-c and d-e), a marker of cell apoptosis.  
 
To better decipher the mechanism of cell cycle arrest in CCA cells 
treated with CAP, we evaluated the activation of the two parallel 
signaling pathways that ultimately break the cell cycle once the 
DNA damage is sensed. These signaling cascades that block the 
progression to mitosis are led by CHK kinases and p53, 
respectively. Western blot analysis from Figure 7b-c and e-f 
showed a strong phosphorylation of both CHK1 and p53 from 24h 
to 72h in both cell lines. These results suggest that the cell cycle is 
arrested soon after CAP-activated culture medium exposure, when 
DNA damage is first detected, but apoptosis is not induced until 
the accumulation of DNA damage is strong enough, that is 72h 
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after exposure to CAP in EGI-1 and 48h in HuCCT1 cells. 
Interestingly, CAP exposure of hepatocytes showed a reduced 
expression of CHK1 and p53 compared to CCA cells 
(Supplementary Figure 2 a), probably due to the low proliferative 
capacity of these cells in primary culture. Additionally, no changes 
in H2AX phosphorylation or PARP cleavage were observed, 
indicating the absence of DNA damage and corroborating the 
selective capacity of CAP (Supplementary Figure 2 a). 
 
 
 
 
 
 
 
 
 
 
Figure 6. (a,d) Representative images of phosphorylated H2AX ( H2AX) 
analyzed by immunofluorescence in EGI-1 (a) and HuCCT1 (d) CCA cells 
after 24, 48h and 72h of exposure to culture medium pretreated with CAP 
for 3 min (9kV, 30kHz, 14%, gap of 7 mm). Magnification, x10. (b,e) 
Representative images of western blot analysis of cleaved PARP, 
phosphorylated and total p53, phosphorylated and total CHK1 and 
phosphorylated H2AX in EGI-1 (b) and HuCCT1 (e) cells treated in the same 
conditions. (c, f) Densitometry analysis of western blot from cleaved 
PARP, phosphorylated p53, phosphorylated CHK1 and phosphorylated 
H2AX. Values are expressed as means ± SEM from 3 independent cultures. 
*, p < 0.05; **, p < 0.01; compared with control cells. 
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When these experiments were reproduced after exposure to 
gemcitabine, we observed similar results in terms of increase of 
H2AX, CHK1 and p53 phosphorylation, accompanied by PARP 
cleavage in both CCA cell lines (Supplementary Figure 2b). 
Interestingly, gemcitabine induces DNA damage in hepatocytes in 
a dose dependent manner (Supplementary Figure 2c), concordant 
with the decrease in viability observed in Figure 4b, and this DNA 
damage started as early as 24h after exposure and was maintained 
until 72h, as ascertained by H2AX phosphorylation 
(Supplementary Figure 2d). However, no change was observed in 
the phosphorylation of CHK1 and p53 or PARP cleavage, indicating 
that the reduction in hepatocyte viability induced by gemcitabine 
may not be related to cell cycle arrest and apoptosis, but other 
types of dead such as necrosis or senescence. 
 
Finally, we verified that the decrease in cell viability of EGI-1 and 
HuCCT1 after CAP treatment was due to apoptosis. Indeed, 
exposure of cells to PAM reduce the number of viable cells and 
increase the populations in the quadrants corresponding to late-
apoptotic and necrotic cells in both cell types (Figure 7a-d), as 
ascertained by Annexin V-7AAD quantification by flow cytometry. 
Of note, this increase in apoptotic cells was observed in HuCCT1 at 
48h, but it was not in EGI-1 at this time (data not shown), becoming 
only evident at 72 h in the later. These results may corroborate 
that apoptosis is not induced until the accumulation of DNA 
damage is strong enough, that is 72h after exposure to PAM in EGI-
1 and 48h in HuCCT1 cells. 
 
 
 
Figure 7. (a-d) Representative images (a, c) and quantification (b, d) of 
apoptosis by flow cytometry analysis of Annexin V/7AAD in EGI-1 (a-b) 
and HuCCT1 (c-d) CCA cells after 48 h of exposure to PAM for 3 min (9kV, 
30kHz, 14%, gap of 7 mm). Values are expressed as means ± SEM from at 
least 3 independent cultures. *, p < 0.05; **, p < 0.01; compared with 
control condition. 
 
II.5. Cold atmospheric plasma affects the 
phenotype of tumor-associated macrophage 
 
Besides effects of CAP on tumor cells, we sought to determine if 
CAP exposure may have any effect on the stroma of the EGI-1 
subcutaneous xenograft model. This model has the advantage of 
providing the opportunity of evaluating the expression of human 
genes, corresponding to the injected tumor CCA cells, and murine 
genes, corresponding to the cells forming the stroma that are 
recruited cancer cells during tumor formation. Therefore, we 
examined the mRNA expression of different specific markers 
corresponding to cancer-associated fibroblasts (CAF) (Acta2, 
coding alpha-SMA), endothelial cells (EC) (Pecam1, coding for 
CD31) and tumor-associated macrophages (TAM) (Adgre1, coding 
for F4/80). There were no significant changes in the mRNA of Acta2 
or Pecam1 among the different groups (Figure 8a). However, the 
expression of Adgre1 increased in the tumors from the animals 
This document is a pre-print version. You may use it at your own convenience although its content may deviate in places from the final published article. 
 
8 
J. Vaquero, F. Judée, M. Vallette, H. Decauchy, A. Arbelaiz, L. Aoudjehane, O. Scatton, E. Gonzalez-Sanchez, F. Merabtene, J. Augustin, C. Housset, T. 
Dufour, L Fouassier, Cancers, 12, 1280 (2020), https://doi.org/10.3390/cancers12051280 
 
that received CAP or gemcitabine treatment compared to the 
controls, suggesting a potential enhanced recruitment and/or 
proliferation of TAMs in the treated tumors (Figure 8a). Presence 
of TAM in tumor from the different groups was evidenced by 
immunohistochemical analyses of F4/80, as shown in 
representative images from each group (Figure 8b), although it 
was impossible to properly determine differences in macrophage 
infiltration by F4/80 IHC quantification. However, based on 
previous publications indicating a phenotypic change of 
macrophages in absence of changes in the total number of these 
cells after exposure to experimental therapies [11], we decided to 
perform a preliminary analysis to elucidate this point. Analysis of 
Ccl2 (coding for Monocyte chemotactic protein-1, MCP-1) and 
Ccr2, a chemokine and its receptor, respectively, which are major 
regulators of monocyte chemotaxis and macrophage trafficking, 
showed an increased expression in groups treated with CAP and 
gemcitabine compared to the controls (Figure 8c), which may 
suggest changes in chemotactic response of resident TAM. In 
addition, CAP was able to increase the expression of several 
cytokines that are associated with the antitumor phenotype of 
macrophages and that are involved in the induction of apoptosis, 
i.e. Tnfa (coding for Tnf), Tnfsf1 (coding for TNF-related 
apoptosis-inducing ligand (Trail)) and Il1b (coding for Il1β) (Figure 
8d). These results are in accord with previous publications that link 
CAP treatment with modulation of immune cells and together with 
the increasing interest of immunotherapies as cancer treatment 
validate the need for further investigation on this topic in CCA. 
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Figure 8. (a) Changes in mRNA expression of cell type markers (Acta2/-
SMA, a marker of cancer-associated fibroblasts CAFs, Pecam1/CD31, a 
marker of endothelial cells (EC) and Adgre1/F4/80, a marker of tumor-
associated macrophages (TAM) in control (white bars), CAP (purple bars) 
and gemcitabine (black bars) treated xenograft tumors. (c) 
Representative IHC staining of F4/80 in the same tumors. Magnification 
x250 (inserts x1000). Scale: 200 µm. (b) Changes in mRNA expression of 
Ccl2/Mcp1 and Ccr2 (c) in control (white bars), CAP (purple bars) and 
gemcitabine (black bars) treated xenograft tumors. (d) Changes in mRNA 
expression of pro-apoptotic cytokines (Tnfa/Tnf, Tnfsf1/Trail and 
Il1b/Il1β) in control (white bars), CAP (purple bars) and gemcitabine 
(black bars) treated xenograft tumors. Values are expressed as means ± 
SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; compared with control 
tumors. 
 
III. Discussion 
 
In the present work, we analyzed the effects of CAP in vivo in a 
mouse xenograft model of CCA and in vitro on human CCA cell lines 
as well as on non-malignant human hepatocytes. We found that 
local application of CAP on the tumor halts its growth without 
inducing systemic side effects. Analysis of tumors showed areas of 
calcification suggesting cell dead, that was confirmed by 
immunostaining of cleaved-caspase-3, a protein of the apoptotic 
pathway, along with DNA lesions due to plasma-originated 
reactive species. In vitro, CAP-activated medium contains reactive 
species (e.g. nitrites) that induced oxidative stress and reduced cell 
survival by arresting the cell cycle and inducing apoptosis in CCA 
cells but not in hepatocytes. Finally, preliminary analysis suggested 
changes in the surrounding stroma of CCA tumors after exposure 
to CAP. 
 
Since the early 2000s, CAP have generated a lot of interest in 
cancer medicine as a promising treatment for cancer without 
inducing systemic toxic side effect. Anti-tumor properties of CAP 
are now well established and tumor volume reductions have been 
demonstrated in murine tumor models of several cancer types 
including pancreatic [12,13], ovary [14], breast [15] and colon [16], 
melanoma [17] and glioblastoma [6,18]. Since CCA is a very 
aggressive tumor with a limited therapeutic arsenal, we 
investigated if CAP may drive to anti-cancer effects in vivo. Based 
on our previous work that aimed to set up a safe device with anti-
tumor properties in CCA [9], we conducted further studies to 
decipher in a deeper way the cellular mechanisms behind CAP 
effect. Up to date the only two studies dealing with the effects of 
CAP on liver cancer were performed in hepatocellular carcinoma 
cell lines [5,8]. Thus, this study is the first conducted on CCA using 
in vivo and in vitro preclinical models. 
 
Owing to the emerging and highly multidisciplinary aspects of 
"cold plasma oncology", only 5% of the studies published so far 
include in vivo experiments [19]. Most CAP studies in cancer have 
been achieved using tumor cell lines originating from either solid 
or blood tumors and rarely on mouse tumor models. We 
conducted in vivo studies to analyze the effects of CAP on death 
and oxidative stress, and we compared this treatment to a 
conventional treatment with gemcitabine. In our study, CAP 
demonstrated anti-tumor properties although a traditional 
chemotherapeutic agent such as gemcitabine showed higher 
efficiency. Interestingly, CAP was applied locally on a very small 
tumor surface for a very short period of time (1 minute) 
demonstrating no side effects, while gemcitabine, that was 
applied intraperitoneally, was accompanied by an increased 
plasmatic concentration of markers indicating liver damage. Even 
if few studies have been performed in vivo, some of them 
confirmed that CAP has no systemic effects. Liedtle et al. have 
addressed this point through a complete study showing that CAP 
by using plasma-activated medium does not affect blood 
parameters, leucocyte distribution or cytokine signature [20]. 
However, classical blood parameters to evaluate liver and cell 
toxicity, such as transaminases and LDH, were not measured, in 
contrast to our study. In spite of our in vitro observation on 
primary hepatocytes and the absence of liver damage in vivo, 
studies using orthotopic CCA model are required to evaluate the 
direct effect of CAP on liver parenchyma. Nevertheless, further 
investigation to improve the surface exposure and the time of 
treatment with CAP is crucial to obtain the maximum benefit from 
this new therapeutic tool. 
 
At cellular level, histology examination of the tumor showed signs 
of calcification, a reaction occurring in response to cell injury, 
indicating the presence of apoptotic tissue. Activation of signaling 
pathways involved in cell death was confirmed by the 
immunohistochemical analysis of cleaved caspase-3 suggesting an 
induction of caspase-3-dependent apoptosis in tumor cells. 
Induction of cell apoptosis is the primary mechanism of CAP action 
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following the reactive species generated by CAP [19]. However, 
other cell death pathways have been recently evidenced such as 
ferroptosis in tumor cells subjected to CAP treatment [21]. In CCA 
cell lines, we tested cell media that were first treated by CAP, i.e. 
PAM. Then PAM was immediately transferred to the cell culture. 
Indirect or direct treatment by CAP displays similar efficacy on 
tumor cell culture, and PAM is also able to reduce tumor burden 
without inducing side effects when injected intraperitoneally in a 
murine model of pancreatic cancer [20]. Intraperitoneal injection 
of PAM lead to reduced metastatic potential of ovarian and gastric 
cancer cells [22,23]. When we evaluated PAM on CCA cells, 
although PAM decreased cell survival in both CCA cell lines with 
similar efficacy, induction of apoptosis was lower in EGI-1 than in 
HuCCT1 cells. Doses of CAP used to treat the medium matters and 
as suggested in previous studies, low doses of CAP can inhibit cell 
proliferation without inducing apoptosis, but instead induce 
senescence [24,25] or autophagy [26,27]. In addition, CAP can 
affect other cell biology features, for example by inducing 
endoplasmic reticulum stress, depolarization of mitochondrial 
membrane potential, DNA damage or by decreasing migratory and 
invasive properties [22,28,29], although these aspects deserve 
further characterization in CCA 
 
At molecular level, we detected DNA double strand breaks in both 
CCA cell lines, along with DNA damage responses with an 
upregulation of the phosphorylation status of p53 and of CHK1, 
both regulating cell cycle checkpoints. We previously observed 
similar DNA damage in CCA cells subjected to oxidative stress with 
hydrogen peroxide [30], suggesting that upon CAP treatment, CCA 
cells may undergo oxidative stress. Overload of RONS in CCA cells 
leads to DNA damage, attested by the phosphorylation of histone 
H2AX, triggering pathways that will ultimately kill the cancer cells 
[31]. Altogether, these results fit perfectly with previous finding in 
other tumors, such as oral cancer, were p53 signaling pathway was 
identified as one of the most deregulated pathways after exposure 
to PAM by using RNA-sequencing approaches [32].  
 
Targeting specifically tumor cells without damaging healthy cells is 
a major challenge of anti-cancer treatment. CAP has the advantage 
to selectively induce cell cycle arrest and death of tumor cells but 
not of healthy ones. Whatever the direct/indirect approach, the 
concept of plasma selectivity is a key issue in treatment. 
Pioneering studies from Babington et al. have shown that the 
plasma treatment of mice bearing subcutaneous glioblastoma led 
to a 56% decrease of tumor volume while maintaining the viability 
of healthy cells surrounding the tumor at 85% [33]. While CAP had 
a significant effect on CCA cancer cells by decreasing cell viability, 
it had no deleterious effect on non-malignant liver cells, i.e. 
primary human hepatocytes, suggesting a selectivity of CAP 
treatment. By killing primarily cancer cells, plasma treatment 
preserves healthy tissue and thereby tissue function. Keidar et al 
were amongst the first to demonstrate a selectivity of CAP on lung 
cancer cell lines versus normal human bronchial epithelial cells 
[34]. This selectivity was also emphasized in melanoma cells 
compared to normal keratinocytes [35], and other cancer types 
(ovarian, glioblastoma), as a general property of CAP [36]. 
However, all these studies deal with cell lines but none with 
primary cells. In our studies, hepatocytes were isolated from 
human liver and cultured according to a well-defined protocol 
[37]. We found that CAP has no impact on hepatocyte survival nor 
the induction of DNA damage or apoptotic regulatory signaling 
pathways, in contrast to CCA cell lines. We chose hepatocytes as 
non-tumor cells because they are the most abundant cell type of 
the liver. Although the media composition, an essential parameter 
[36], was not the same between the two cell types, CAP generated 
the same profile of RNS in both media and higher ROS in 
hepatocyte media. Furthermore, hydrogen peroxide increased in 
CCA cell lines after exposure to PAM, as previously described for 
atmospheric pressure plasma jets [38], while it remained 
unchanged in hepatocytes. The cellular mechanisms by which CAP 
operates this selectivity are still poorly understood and indirect 
evidence exist to explain this crucial issue. Among the potential 
mechanisms given so far aquaporins and anti-oxidant cellular 
defense systems seem to be the most plausible explanations [4]. 
Indeed, as happened in our study, elevated expression of ROS-
scavenging enzymes such as superoxide dismutase, catalase and 
glutathione reductase has been observed in healthy cells 
compared to tumor cells, which may contribute to cellular defense 
against CAP-originated reactive species [4]. 
 
Finally, one major point that should be considered when a tumor 
is treated by CAP is its potential effect on the tumor 
microenvironment cells. Tumor is a mix of several cell types 
including tumor cells but also CAF, EC and TAM. According to 
histological examination of CCA tumors treated with CAP, fibrotic 
stroma is not affected by CAP treatment, a result that is confirmed 
by unchanged mRNA expression level of a-SMA, a marker of CAF, 
between treated and untreated conditions. As previously shown, 
fibroblasts are less affected by CAP compared to cancer cells 
[20,39]. No obvious change in vascularization is observed even if 
plasma has been shown to suppress neovascularization but not 
pre-existing vessels, an effect that is partly independent of ROS 
[40]. Further studies must be conducted in the case of CCA to 
confirm or not a potential action of CAP on vascular system. 
Interestingly, one of the most promising views is that CAP 
treatment is able to activate the immune response to attack the 
tumor [16,41,42]. Indeed, our analysis on tumor xenografts 
showed changes in the expression of markers related to TAM 
phenotype, suggesting a potential shift towards an anti-tumor 
phenotype of TAM, although this issue deserves further 
consideration and new research will be undertaken. In vitro 
studies performed by other groups are in agreement with our 
findings in vivo, suggesting that increasing the function of pro-
inflammatory macrophages may help to control tumorigenesis 
caused by compromised immune response [41]. Taking into 
account that one of the most therapeutic strategies under study 
nowadays is the activation of the patient immune system to fight 
tumors, it is imperative to keep deepening on the molecular 
mechanisms implicated in the effects of CAP on the immune 
system, especially in immunocompetent murine cancer models in 
which not only macrophages but also lymphocytes could be 
potentially involved in this response. 
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IV. Materials and Methods 
 
IV.1. Cell culture and treatment 
 
HuCCT1 cells, derived from intrahepatic biliary tract, were kindly 
provided by Dr. G. Gores (Mayo Clinic, MN). EGI-1 cells, derived 
from extrahepatic biliary tract, were obtained from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, Germany). 
Cells were cultured in DMEM supplemented with 1 g/L glucose, 10 
mmol/L HEPES, 10% fetal bovine serum (FBS), antibiotics (100 
UI/mL penicillin and 100 mg/mL streptomycin), and antimycotic 
(0.25 mg/mL amphotericin B). Cell lines were routinely screened 
for the presence of mycoplasma and authenticated for 
polymorphic markers to prevent cross-contamination. 
 
IV.2. Isolation and culture of human 
hepatocytes  
 
Normal liver tissue was obtained from adult patients undergoing 
partial hepatectomy for the treatment of colorectal cancer 
metastases. Primary human hepatocyte isolation was performed 
on the Human HepCell platform (IHU-ICAN, Paris, France, 
http://www.ican-institute.org/category/plateformes) as 
previously described [43]. Ethical approval for the isolation of 
human hepatocytes was granted by the Persons Protection 
Committee (CPP Ile de France III) and by the French Ministry of 
Health (N°: COL 2929 and COL 2930). Hepatocytes were isolated 
using an established two-step-perfusion protocol with 
collagenase. First, the tissue was rinsed with pre-warmed (37 °C) 
calcium-free buffer supplemented with 5 mmol/L ethylene glycol 
tetraacetic acid (Sigma, Saint-Quentin Fallavier, France). Then, the 
liver sample was perfused with recirculating perfusion solution 
containing 5 mg/mL of collagenase (Sigma) at 37 °C. Afterwards, 
the tissue was transferred into a petri dish containing a 
Hepatocyte Wash Medium (Life technologies, Villebon sur Yvette, 
France). Tissue was disrupted mechanically by shaking and using 
tweezers to disrupt cells from the remaining scaffold structures. 
Cellular suspension was filtered through a gauze-lined funnel. Cells 
were centrifuged at low speed centrifugation (50 g). The 
supernatant was removed, and pelleted hepatocytes were re-
suspended in Hepatocyte Wash Medium. Viability cell was 
determined by trypan blue exclusion test. Freshly isolated normal 
hepatocytes were suspended in Williams’ medium E (Life 
Technologies) containing 10% fetal calf serum (FCS) (Eurobio, 
Courtaboeuf, France) penicillin-streptomycin (penicillin: 200 
U/mL; streptomycin: 200 g/mL) and insulin (0,1 U/mL). Then, the 
cells were seeded in 6 and 96 well plates pre-coated with type I 
collagen at a density of 1.8 x106 and 0.5 x105 viable cells/well, 
respectively, and incubated at 37°C in a 5% CO2 overnight. Then, 
the medium was replaced with fresh complete hepatocyte 
medium supplemented with 1 µmol/L hydrocortisone 
hemisuccinate (SERB, Paris, France) and cells were left in this 
medium until treatment with plasma activated medium (PAM). 
 
IV.3. Xenograft tumor model 
 
Animal experiments were performed in accordance with the 
French Animal Research Committee guidelines and all procedures 
approved by a local ethic committee (No 10609). 2 × 106 of EGI-1 
cells were suspended in 60 μL of PBS and 60 μL of Matrigel® growth 
factor reduced (Corning) and implanted subcutaneously into the 
flank of 5-week-old female ATHYM-Foxn1 nu/nu mice (Janvier 
Labs, France). Mice were housed under standard conditions in 
individually ventilated cages enriched with a nesting material and 
kept at 22 °C on a 12 h light/12 h dark cycle with ad libitum access 
to food and tap water. Tumor growth was monitored by measuring 
every 2–3 days the tumor volume (V xenograft) with a caliper as 
follows: V xenograft = x·y2/2 where x and y are the longest and 
shortest lateral diameters respectively. Once tumor volume 
reached approximately 200 mm3, CAP and gemcitabine 
treatments were initiated. Gemcitabine was administered every 
Monday and Thursday during 3 weeks by intraperitoneal injection 
at a concentration of 120 mg/kg dissolved in saline solution 
(vehicle). Cold atmospheric plasma was administered as explained 
in section 4.4 the same days as gemcitabine. 
 
IV.4. Cold atmospheric plasma treatment 
 
The in vivo and the in vitro experiments were conducted using the 
same atmospheric pressure plasma jet device, called PTJ, as 
sketched in Figure 1a. It is composed of a 10 cm long dielectric 
quartz tube presenting a 4 mm inner diameter and a 2 mm wall 
thickness. Its electrode configuration is made of two outer ring 
electrodes with inner and outer diameters of 8mm and 12.8 mm 
respectively while the inter-ring distance is 50 mm. For all 
experiments, the lower ring electrode was connected to the 
ground while the upper ring electrode was biased to the high 
voltage. The PTJ was supplied with helium gas (flow rate of 1 slm) 
and powered with a nanopulse high voltage generator device 
(model Nanogen 1) from RLC Electronic company. For both in vivo 
and in vitro experiments, electrical parameters were fixed as 
follows: 9 kV of amplitude, 14% of duty cycle and 30 kHz of 
repetition frequency. The reasons explaining how these values 
were chosen as well as the physico-chemical characterizations of 
the PTJ device have already been published in [9]. For the in vivo 
studies, the cold atmospheric plasma was applied to the animals 
as previously described [9], 9kV, 30kHz, 14%, maintaining a gap of 
10 mm between the tube and the skin. For the in vitro studies, cells 
were treated with PAM. In order to maintain reproducibility 
among different plastic supports, 3 mL of the corresponding 
culture media in a 6-well plate were treated with the same 
conditions (9kV, 30kHz, 14%) during 1, 3, 5 or 10 min. A gap of 7 
mm between the tube and the surface of medium was constantly 
maintained. After treatments, PAM was transferred to 96-, 24- or 
6-well plates according to the different analysis performed 
(Supplementary Figure 1). 
 
IV.5. Biochemistry  
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The concentrations of alanine aminotransferase (ALAT), aspartate 
aminotransferase (ASAT), and lactate dehydrogenase (LDH) in 
plasma of mice, were measured on an Olympus AU400 Analyzer.  
 
IV.6. Histology and (immuno)histochemistry 
 
Formalin-fixed paraffin-embedded tissue samples from mice 
xenografts were cut in 4 μm sections, deparaffined and stained 
with hematoxylin and eosin to observe tissue histology.  
For immunohistochemistry, antigens were unmasked as indicated 
in Table 1. For cleaved-caspase-3 and 8-oxoguanine, sections were 
sequentially incubated with H2O2 for 5 minutes (only for caspase3), 
with Protein Block (Novolink Polymer Detection System; 
Novocastra Laboratories Ltd.) for 5 minutes, and with primary 
antibodies for 30 minutes (overnight for 8-oxoguanine). Novolink 
Post Primary was applied for 15 minutes. Sections were finally 
washed and incubated with Novolink Polymer for 15 minutes. An 
automated staining system (Autostainer Plus, Dakocytomation) 
was used to perform immunostaining. The color was developed 
using amino-ethyl-carbazole (AEC peroxidase substrate kit; Vector 
Laboratories). Sections were counterstained with hematoxylin and 
mounted with glycergel (Dako). For F4/80 sections were incubated 
with PBS 0.5% triton X-100 30 minutes to increase the 
permeabilization of the tissue. Then, they were blocked with horse 
serum 2.5% (Vector) during 1h. After tissue blocking, samples were 
immunostained with primary antibody overnight at 4°C. Then, 
endogenous peroxidase blocking was performed with hydrogen 
peroxide solution (Leica) during 1h. Samples were developed with 
the ImPRESS Excel staining kit (Vector) following manufacturer 
instruction. Briefly, tissue samples were incubated with anti-rabbit 
Ig secondary antibody for 1h30, washed with PBS, and incubated 
with an anti-goat amplifier antibody for 1h. Finally, the samples 
were developed with peroxidase substrate for 3 minutes and 
counterstain with Mayer’s hematoxylin (Dako) 5 minutes. 
 
 
IV.7. Cell viability 
 
5000 EGI-1 cells/well, 4000 HuCCT1 cells/well and 50,000 
hepatocytes/well were plated in 96-well plates. 24 h later, the 
medium was replaced by fresh culture medium, PAM or 
gemcitabine. Cells were then incubated for 72 hours before 
determining the viability by the crystal violet method. Absorbance 
was quantified with a spectrophotometer (Tecan) at 595 nm. 
 
IV.8. RONS determination in culture media 
To verify whether reactive species are produced in PAM, nitrites 
and H2O2 concentrations were measured using Griess reagent 
(Sigma Aldrich) and Titanium Sulfate TiSO4 (Sigma-Aldrich) 
respectively. In presence of nitrite species, the Griess reagent 
shows an absorption peak at 518nm (pink coloration) while in 
presence of peroxide, the TiSO4 shows an absorption peak at 
405nm (yellow coloration) both measured with the Biotek Cytation 
3 device. A two-steps protocol was followed: first, the media were 
placed in 6 well-plates and exposed to plasma as previously 
explained in section 4.4. Second, plasma was switched off. For the 
nitrite determination, 25 mL of each culture media sample was 
mixed with 175 mL of distilled water and 50 mL of Griess reagent. 
For the peroxide determination, 250 mL of each culture media 
sample was mixed with 100 mL of TiSO4. 
 
IV.9. ROS determination in cell lysates 
 
ROS production was assessed using the 2′,7′-dichlorofluorescein 
diacetate (H2DCFDA; Abcam cat number ab113851) according to 
the instructions. Briefly, CCA cells and hepatocytes were plated at 
2.5 x105 cells/well and 0.5 x105 cells/well, respectively, in black-
walled, clear-bottom 96-well microplates, and incubated for 24 h 
at 37 °C. The cells were incubated with CM-H2DCFDA (25 μM) in 
PBS for 30 min and then with PAM for 30 min. Cells were washed 
with PBS, and fluorescence was measured at 485/535nm (Tecan). 
Normalization was done by crystal violet method. 
 
IV.10. Apoptosis assay 
 
2x105 EGI-1 cells/well and 1.5x105 HuCCT1 cells/well were plated 
in 6-well plates. 24 h later, the medium was replaced by fresh 
culture medium or PAM. 48h or 72h later both cells from the 
supernatant and the plates were collected and stained using the 
PE Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend), 
according to the manufacturer’s instructions. Flow-cytometric 
analysis was performed using a Gallios flow cytometer (Beckman-
Coulter) to calculate the apoptosis rate. Results were analyzed 
using Kaluza analysis software (Beckman-Coulter). 
 
IV.11. Immunofluorescence 
 
Table 1. Primary antibodies used for immunodetection. 
Name Species 
Manu- 
facturer 
Reference Dilution 
Antigen 
unmasking 
8-oxoguanine M Abcam ab206461 1/100 (IHC) EDTA pH8 
cCaspase3 R CST CST9664 1/100 (IHC) 
Citrate 
pH6 
cPARP R CST CST5625 1/1000 (WB)  
CHK1 M CST CST2360 1/1000 (WB)  
pCHK1 R CST CST2348 1/1000 (WB)  
F4/80 R 
Spring 
Bioscience 
M4154 1/100 (IHC) 
Citrate 
pH6 
GAPDH M Santa Cruz sc-32233 1/5000 (WB)  
p53 M Santa Cruz sc-126 1/500 (WB)  
pp53 R CST CST9284 1/1000 (WB)  
H2A.X R CST CST9718 
1/1000 (WB), 
1/200 (IF) 
 
M, mouse; R, rabbit; WB, western blot; IF, immunofluorescence; IHC, 
immunohistochemistry. 
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Immunofluorescence assays were performed as previously 
described [44]. Primary antibodies are provided in Table 1. Cells 
were observed with an Olympus Bx 61 microscope (Olympus). 
 
IV.12. Western blot analysis 
 
For obtaining whole-cell lysates for WB, cell cultures were lysed in 
RIPA buffer supplemented with 1 mmol/L orthovanadate and a 
cocktail of protease inhibitors. Proteins were quantified using a 
BCA kit (Pierce). WB analyses were performed as previously 
described [44]. Primary antibodies are provided in Table 1. 
 
IV.13. Cell cycle analysis 
 
0.6x105 EGI-1 cells/well and 0.5x105 HuCCT1 cells/well were 
seeded in 6-well plates and incubated for 24 h. The cells were then 
treated with PAM for 24h. Cells are detached with trypsin, washed 
with cold PBS, pooled, and centrifuged before being fixed in 70% 
ice-cold ethanol during 30 min at -20°C, and stored at −20 °C if 
required. Cells are incubated with 100 μg/mL of RNase A and 
40 μg/mL of propidium iodide in PBS buffer. The stained cells were 
analyzed with a CytoFLEX (Beckman-Coulter), and their 
distribution in different phases of the cell cycle was calculated 
using Kaluza analysis software. 
 
IV.14. RNA and reverse transcription-PCR 
 
Total RNA extraction and RT-qPCR was performed as previously 
described [44]. Primer sequences are provided in Table 2. Gene 
expression was normalized to Hprt1 mRNA content for mouse 
genes and was expressed relatively to the control condition of 
each experiment. The relative expression of each target gene was 
determined from replicate samples using the formula 2- Ct. 
 
 
Table 2. Mouse primer used for quantitative real-time PCR. 
Gene Protein Forward (5’→3’) Reverse (5’→3’) 
Acta2 -Sma CTGTCAGGAACCCTGAGACGCT TACTCCCTGATGTCTGGGAC 
Pecam1 CD31 AGCCTCCAGGCTGAGGAAAA GATGTCCACAAGGCACTCCA 
Ccr2 Ccr2 GGCCACCACACCGTATGACTA AGAGATGGCCAAGTTGAGCAGATAG 
Adgre1 F4-80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
Il1b Il1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
Ccl2 Mcp1 GCCTGCTGTTCACAGTTGC CAGGTGAGTGGGGCGTTA 
Tnfa Tnfa CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
Tnfsf10 Trail GCTCCTGCAGGCTGTGTC CCAATTTTGGAGTAATTGTCCTG 
Hprt1 Hprt TCAGTCAACGGGGGACATAA TGCTTAACCAGGGAAAGCAAA 
 
IV.15. Statistics 
 
Results were analyzed using the GraphPad Prism 5.0 statistical 
software. Data are shown as means ± standard error of the mean 
(SEM). For comparisons between two groups, parametric Student 
t test or nonparametric Mann–Whitney test were used. For 
comparisons between more than two groups, parametric one-way 
ANOVA test followed by a posteriori Bonferroni test was used. 
V. Conclusions 
 
Our results indicate that CAP is able to reduce CCA progression 
through induction of DNA damage, which leads to cell cycle arrest 
and apoptosis of tumor cells, together with potential effects in the 
immune microenvironment in terms of phenotypic change of 
TAM. These evidences support the potential usefulness of CAP as 
a future tool to treat CCA. However, several questions remain to 
be solved before reaching application in CCA patients. First, effect 
of CAP on healthy liver cells must be evaluated in preclinical 
orthotopic models of CCA to assess the level of side damaging 
effects after a direct CAP treatment to the liver. Moreover, to 
reach human applicability, the size of the CAP applicating device 
must be reduced and adapted to the human anatomy and 
localization of biliary tumors. Therefore, although CAP is a novel 
promising anticancer “agent”, further investigation is needed to 
include it in the therapeutic arsenal of CCA in the future. 
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VII. Supplement materials 
 
 
Supplementary Figure 1. Schematic representation of in vitro treatment 
of CCA cell lines and hepatocytes with PAM. (a) 3 ml of fresh culture media 
is added into an empty well of a 6-well plate. (b) Fresh culture media is 
treated with CAP during 1, 3, 5 or 10 minutes to generate PAM. (c) PAM 
is collected and dispatched in different plastic supports (i.e. 6-well, 24-
well or 96-well plates) previously plated with CCA cell lines or 
hepatocytes. Then plates are developed by different methods at different 
time points as explained in the manuscript section Materials and 
Methods. 
 
 
 
Supplementary Figure 2. (a) Representative images of western blot 
analysis of cleaved PARP, phosphorylated and total p53, phosphorylated 
and total CHK1 and phosphorylated H2AX in hepatocytes after 24, 48h 
and 72h of exposure to culture medium pretreated with CAP for 3 min 
(9kV, 30kHz, 14%, gap of 7 mm). (b, c) Representative images of western 
blot analysis of cleaved PARP, phosphorylated and total p53, 
phosphorylated and total CHK1 and phosphorylated H2AX in EGI-1 and 
HuCCT1 after 24, 48h and 72h of exposure to 0.1 and 0.01 μM of 
gemcitabine, respectively. (d) Representative images of western blot 
analysis of cleaved PARP, phosphorylated and total p53, phosphorylated 
and total CHK1 and phosphorylated H2AX in EGI-1 and HuCCT1 after 72h 
of exposure to increasing doses of gemcitabine. (e) Representative 
images of western blot analysis of cleaved PARP, phosphorylated and 
total p53, phosphorylated and total CHK1 and phosphorylated H2AX in 
EGI-1 and HuCCT1 after 24, 48h and 72h of exposure to 10 μM of 
gemcitabine. 
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In the following pages we show the western blots performed with 
3 different cultures of EGI-1 and HuCCT1 cholangiocarcinoma 
(CCA) cells exposed to plasma activated medium (PAM), that were 
quantified to generate the graphs showed in Figure 7 from the 
manuscript. The densitometry original data from each of the 
proteins that were quantified (gammaH2AX, pp53, pCHK1, cPARP 
and GAPDH) is shown below the corresponding band. We also 
show the original capture from the PageRuler™ Prestained Protein 
Ladder (Biorad) taken for each protein and the closer molecular 
weight marker (PageRuler™ Prestained Protein Ladder, 
Thermofisher) to each band. 
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